

Tuberculosis profile: Japan

Population 2022: 124 million

Estimates of TB burden*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	12 000 (10 000-14 000)	9.5 (8.1-11)
HIV-positive TB incidence	62 (22-120)	0.05 (0.02-0.1)
MDR/RR-TB incidence**	420 (0-900)	0.34 (0-0.72)
HIV-negative TB mortality	3 200 (3 000-3 400)	2.6 (2.4-2.7)
HIV-positive TB mortality	15 (5-32)	0.01 (0-0.03)

Estimated proportion of TB cases with MDR/RR-TB*, 2022

New cases	2.6% (0.51-7.1)
Previously treated cases	17% (1.5-59)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2022	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2022	29% (25-34)

TB case notifications, 2022

Total new and relapse	10 235
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	6.2%
- % pulmonary	73%
- % bacteriologically confirmed ^	88%
- % children aged 0-14 years	<1%
- % women (aged ≥15 years)	41%
- % men (aged ≥15 years)	59%
Total cases notified	10 235

TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	25	3.9%
- on antiretroviral therapy		

Drug-resistant TB care**, 2022

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	63%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	57%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	
MDR/RR-TB cases tested for resistance to any fluoroquinolone	

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	64%	11 448
Previously treated cases, excluding relapse, registered in 2021		
HIV-positive TB cases registered in 2021	69%	29
MDR/RR-TB cases started on second-line treatment in 2020	71%	55
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020		

TB preventive treatment, 2022

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	8.5% (8.3-8.8)

* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.


** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

^ Calculated for pulmonary cases only


^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)



HIV-negative TB mortality (Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2022 (Number)



Cases attributable to five risk factors, 2022 (Number)

